Overactive Bladder News and Research

RSS

Overactive bladder (OAB) is a urological condition defined by a set of symptoms: "urgency, with or without urge incontinence, usually with frequency and nocturia."

Targacept plans to pursue development of TC-5214 for overactive bladder

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that it plans to pursue development of TC-5214 as a treatment for overactive bladder (OAB).

6 Sep 2012

Link between sleep apnoea and overactive bladder syndrome in women

Sleep apnoea in women has been linked to overactive bladder syndrome in a new study. The research, presented at the European Respiratory Society's Annual Congress in Vienna, has provided new evidence suggesting a connection between the two conditions.

3 Sep 2012

Uroplasty first quarter global sales increase 20% to $5.6 million

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the first quarter of fiscal 2013 ended June 30, 2012.

26 Jul 2012

Nerve growth factors sense OAB in children

Researchers may have found a reliable biomarker for diagnosing overactive bladder in children and monitoring their treatment outcome.

18 Jul 2012

Astellas Pharma receives FDA approval for Myrbetriq to treat overactive bladder

The U.S. Food and Drug Administration today approved Myrbetriq (mirabegron) to treat adults with overactive bladder, a condition in which the bladder muscle cannot be controlled, squeezes too often or squeezes without warning.

29 Jun 2012

Positive results from Antares Pharma's VIBEX MTX human factors usability study for RA

Antares Pharma, Inc. today announced positive results from a human factors usability study for VIBEX Methotrexate (MTX), a proprietary auto injector product designed to self-administer a rapid subcutaneous weekly injection of methotrexate for the treatment of rheumatoid arthritis (RA).

26 Jun 2012

AUA Foundation introduces It's Time to Talk About OAB campaign

On the heels of the fourth annual World Continence Week, the American Urological Association (AUA) Foundation has launched "It's Time to Talk About OAB," a nationwide education campaign designed to elevate awareness of Overactive Bladder (OAB), a common, yet often untreated condition, as a public health issue.

20 Jun 2012

US Court of Appeals confirms District Court decision in Watson's Sanctura XR patent suit

Watson Pharmaceuticals, Inc. today confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the District of Delaware's March 31, 2012 decision that the asserted claims of U.S. Patent Nos. 7,410,978; 7,759,359; 7,781,448; 7,781,449 and 7,763,635 relating to Sanctura XR (trospium chloride extended-release capsules) are invalid.

19 Jun 2012

AUA includes percutaneous tibial nerve stimulation in OAB treatment guidelines

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that the American Urological Association (AUA) issued a clinical guideline titled "Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults," which includes percutaneous tibial nerve stimulation (PTNS) as an integral part of the care path for overactive bladder (OAB) treatment.

22 May 2012

AltheRx reports positive Phase II results of Solabegron for OAB

AltheRx Pharmaceuticals, a privately-held clinical development company, presented positive results from its Phase II study of Solabegron in overactive bladder (OAB) at the American Urological Association Annual Meeting (Abstract # 520).

21 May 2012

Teva announces new data from women's health franchise

Teva Women's Health today announced new data from the Company's expanding women's health franchise will be featured at the 60th Annual Clinical Meeting of the American Congress of Obstetricians and Gynecologists (ACOG) in San Diego, California, May 5-9, 2012.

5 May 2012

CMAJ outlines possible causes and treatments for bedwetting in children

Bedwetting in older children is common, but it can be distressing. An article in CMAJ (Canadian Medical Association Journal) outlines possible causes and evidence for current treatments.

24 Apr 2012

Astellas' mirabegron for OAB receives FDA advisory committee approval

Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the Reproductive Health Drugs Advisory Committee of the U.S. Food and Drug Administration voted that the overall risk/benefit assessment supports approval of mirabegron for the treatment of overactive bladder.

6 Apr 2012

Positive results from Allergan's BOTOX Phase III trials on idiopathic overactive bladder

Allergan, Inc. today announced that two Phase III clinical trials of BOTOX (onabotulinumtoxinA) as a potential treatment option for patients with idiopathic overactive bladder met their pre-specified primary endpoints.

29 Mar 2012

FDA approves Botox injections for overactive bladder

When you think of Botox injections, you probably think of getting rid of unwanted wrinkles around the eyes or forehead, but recently the US Food and Drug Administration (FDA) approved using the injections to help patients with neurological conditions who suffer from incontinence, or an overactive bladder.

14 Mar 2012

Botox - a potential for therapy of weak bladders in women

The study, published in the journal European Urology, was carried out at eight uro-gynecology centers in the UK from 2006 to 2009 by researchers from the University of Leicester. A total of 240 women were split into two groups, with 122 women given Botox and 118 receiving a dummy treatment. Researchers found improvements across a range of symptoms, including wetting oneself and feeling a need to rush to the toilet, and how often the women 'leaked' urine.

13 Mar 2012

Antares Pharma fourth quarter revenues increase 65% to $5.4 million

Antares Pharma, Inc. today reported financial and operating results for the fourth quarter and full year ended December 31, 2011 and outlined key objectives and milestones for 2012.

12 Mar 2012

Botulinum toxin effective in treating OAB among women

The biggest study into the treatment of urinary incontinence with botulinum toxin (trade name Botox) has demonstrated that it is effective in treating overactive bladder (OAB) - a debilitating common condition which can affect up to 20% of people over the age of 40.

12 Mar 2012

Positive results from AltheRx Solabegron Phase II study on overactive bladder

AltheRx Pharmaceuticals, a privately-held clinical development company, presented positive results from its Phase II study of Solabegron in overactive bladder (OAB) at the European Association of Urology Congress in Paris.

1 Mar 2012

ROSETTA Study to compare two therapies in women with overactive bladder

Overactive bladder, or the sudden urge to urinate, affects the quality of life of many women. Studies have shown that not all women respond to or can tolerate oral medications and may benefit from other therapies.

1 Mar 2012